- Conjeevaram H, Everhart J, Hoofnagle J. Predictors of sustained beneficial response to interferon alfa therapy in chronic hepatitis C. Hepatology 1995; 22: 1326–9.
- Chemello L, Bonetti P, Cavaletto L, Talato F, Donadon V, Casarin P, Belussi F, Frezza M, Noventa F, Pontisso P, Benvegnù L, Casarin C, Alberti A. and the TriVeneto Viral Hepatitis Group. Randomized trial comparing three different regimens of alfa-2a-interferon in chronic hepatitis C. Hepatology 1995; 22: 700–6.
- Martinot-Peignoux M, Marcellin P, Poteau M, Castelnau C, Boyer N, Poliquin M, Degott C, Descombes I, Le Breton V, Milotova V, Benhamou JP, Erlinger S. Pretreatment serum HCV RNA levels and hepatitis C virus genotype are the main and independant prognostic factors of sustained response to interferon alfa therapy in chronic hepatitis C. Hepatology 1995; 22: 1050–6.
- Hayashi J, Kishihara Y, Ueno K, Yamaji K, Kawakami Y, Furusyo N, Sawayama Y, Kashiwagi S. Age-related response to interferon alfa treatment in women vs men with chronic hepatitis C virus infection. Arch Intern Med 1998; 158: 17781.
- Poynard T, Leroy V, Cohard M, Thevenot T, Mathurin P, Opolon P, Zarski JP. Meta-analysis of interferon randomized trials in the treatment of viral hepatitis C: effects of dose and duration. Hepatology 1996; 24: 778–89.
- Garson J, Uhnoo I, Whitby K, Braconier JH, Deaville R, Duberg A, Wallmark E, Wiström J, Goldin RD, Spacey B. Virological, biochemical and histological effects of human lymphoblastoid interferon in Swedish patients with chronic hepatitis C. J Viral Hepat 1997; 4: 325–31.
- Weiland O, Chen M, Lindh G, Mattsson L, Schvarcz R, Sönnerborg A, Wahl M, Wejstål R, Widell A, Norkrans G. Efficacy of human leucocyte alfa-interferon treatment for chronic hepatitis C virus infection. Scand J Infect Dis 1995; 17: 319–24.
- Reichard O, Foberg U, Fryden A, Mattsson L, Norkrans G, Sönnerborg A, Wejstål R, Yan Z-B, Weiland O. High sustained response rate and clearance of viraemia in chronic hepatitis C following treatment with interferon alfa-2b for 60 weeks. Hepatology 1994; 19: 280–5.
- Reichard O, Norkrans G, Frydén A, Braconier J, Sönnerborg A, Weiland O. Randomised, double-blind, placebo-controlled trial of interferon alfa-2b with and without ribavirin for chronic hepatitis C. Lancet 1998; 351: 83–7.
- Urdea M, Horn T, Fultz T, Anderson M, Running JA, Hamren S, Ahle D, Chang CA. Branched DNA amplification multimers for the sensitive, direct detection of human hepatitis viruses. Nucl Acids Symp Ser 1991; 24: 197–200.
- Whitby K, Garson J. Optimisation and evaluation of a quantiotative chemiluminescent polymerase chain reaction assay for hepatitis C virus RNA. J Virol Methods 1995; 51: 75–88.
- Yun Z, Lundeberg J, Johansson B, Hedrum A, Weiland O, Uhlén M, Sönnerborg A. Colorimetric detection of competitive PCR products for quantification of hepatitis C viremia. J Virol Methods 1994; 47: 1–14.
- Stuyver L RL, Wyseur A, Duhamel M, Vanderborght B, Van Heuverswyn H, Maertens G. Typing of hepatitis C virus isolates and characterization of new subtypes using a line probe assay. J Gen Virol 1993; 74: 1093–102.
- Widell A, Shev S, Månsson S, Zhang YY, Foberg U, Norkrans G, Fryden A, Weiland O, Kurkus J, Nordenfelt E. Genotyping of hepatitis C virus isolates by a modified PCR assay using type specific primers: epidemiological applications. J Med Virol 1994; 44: 272–9.
- Yun Z, Reichard O, Chen M, Lundeberg J, Norkraus G, Frydin A, Sönnerborg A, Weiland O. Serum hepatitis C virus RNA levels in chronic hepatitis C – importance for outcome of interferon alfa-2b treatment. Scand J Infect Dis 1994; 26: 263–70.
- Reichard O, Norkrans G, Frydén A, Braconier J-H, Sönnerborg A, Weiland O. Comparison of three quantitative HCV RNA assays – accuracy of baseline viral load to predictor treatment outcome in chronic hepatitis C. Scand J Infect Dis 1998; 30: 441–6.
- Poynard T, Marcellin P, Lee SS, Niederau C, Minuk GS, Ideo G, Bain V, Hethcote J, Zeuzem S, Trepo C, Albrecht J, for the International Hepatitis Interventional Therapy Group. Randomised trial of interferon alfa-2b plus ribavirin for 48 weeks or 24 weeks versus interferon alfa-2b plus placebo for 48 weeks for treatment of chronic infection with hepatitis C virus. Lancet 1998; 352: 1426–32.
- McHutchinson JG, Gordon SC, Schiff ER, Shiffman ML, Le WM, Rustgi VK, Goodman ZD, Ling M-H, Cort S, Albreight J, for the Hepatitis Interventional Therapy Group. Interferon alfa-2b alone or in combination with ribavirin as initial therapy for chronic hepatitis C. N Engl J Med 1998; 339: 1485–92.
- Lam N, Neumann A, Gretch D, Wiley T, Perelson A, Layden T. Dose-dependent acute clearance of hepatitis C genotype 1 virus with interferon alfa. Hepatology 1997; 26: 226–31.
- Weiland O. Can HCV infection be cleared? Lancet 1998; 352: 669–70.
Scandinavian Journal of Infectious Diseases
Volume 31, 1999 - Issue 2